- Home
- / Kura Oncology
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Kura Oncology financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$17.4
2024-10-29
Market Capitalization
$1.3 B
2024-10-29
Revenue
$67.5 M
FY, 2025
CreditSafe Score
?
Score changed on Jun 09, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 53.9M | 67.5M | |||||||||||||
| General and administrative expense | 23.4K | 22.3K | 22.7K | 23.9K | 19.7M | 31.5M | 46.5M | 47.1M | 50.6M | 77.1M | |||||
| Operating expense total | 23.4K | 22.3K | 22.7K | 23.9K | 67.5M | 91.9M | 139.9M | 165.8M | 247.1M | ||||||
| Depreciation and amortization | 20.0K | ||||||||||||||
| EBIT | (23.4K) | (22.3K) | (22.7K) | (23.9K) | (193.2M) | ||||||||||
| EBIT margin, % | -358.5% | ||||||||||||||
| Interest income | 128.0K | 499.0K | 751.0K | 3.2M | 4.7M | 2.8M | 1.2M | 4.3M | 14.7M | 22.8M | |||||
| Interest expense | 3.6K | 5.0K | 5.9K | 6.8K | 1.2M | 807.0K | 643.0K | 2.4M | 4.3M | 1.5M | 1.1M | ||||
| Pre tax profit | (172.0M) | (278.4M) | |||||||||||||
| Income tax expense | 2.0M | 297.0K | |||||||||||||
| Net Income | (27.0K) | (27.3K) | (28.6K) | (30.7K) | (22.6M) | (27.6M) | (35.4M) | (60.4M) | (63.1M) | (89.6M) | (130.5M) | (135.8M) | (152.6M) | (174.0M) | |
| EPS | (2.0) | (2.1) | (2.0) | (3.2) |